Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy

References

• Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017 Jun 22;129(25):3322–3331.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 Anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017 Jan 4;25(1):285–295.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):439–448.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019 Jan 3;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25.
   PubMed Web of Science ®Google Scholar
• Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):449–459.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016 Sep 7;8(355):355ra116.
   PubMed Web of Science ®Google Scholar
• Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017 Nov 23;130(21):2295–2306.
   PubMed Web of Science ®Google Scholar
• O’Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019 Feb 15;25(4):1142–1146.
   PubMed Web of Science ®Google Scholar
• Bouchkouj N, Kasamon YL, de Claro RA, et al. FDA Approval Summary: axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma. Clin Cancer Res. 2019 Mar 15;25(6):1702–1708.
   PubMed Web of Science ®Google Scholar
• FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. 2018 [cited 2019 Sept 27]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma
   Google Scholar
• Hay KA, Turtle CJ. Chimeric Antigen Receptor (CAR) T Cells: lessons learned from targeting of CD19 in B-Cell malignancies. Drugs. 2017 Mar;77(3):237–245.
   PubMed Web of Science ®Google Scholar
• Marcucci KT, Jadlowsky JK, Hwang WT, et al. Retroviral and lentiviral safety analysis of gene-modified T Cell products and infused HIV and oncology patients. Mol Ther. 2018 Jan 3;26(1):269–279.
   PubMed Web of Science ®Google Scholar
• Lyon D, Lapteva N, Gee AP. Absence of replication-competent retrovirus in vectors, T Cell products, and patient follow-up samples. Mol Ther. 2018 Jan 3;26(1):6–7.
   PubMed Web of Science ®Google Scholar
• Cornetta K, Duffy L, Turtle CJ, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T Cell products. Mol Ther. 2018 Jan 3;26(1):280–288.
   PubMed Web of Science ®Google Scholar
• Cruz CR, Hanley PJ, Liu H, et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010 Oct;12(6):743–749.
   PubMed Web of Science ®Google Scholar
• Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018 Jan 4;131(1):121–130.
   PubMed Web of Science ®Google Scholar
• Park JH, Romero FA, Taur Y, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-Cell acute lymphoblastic leukemia treated with chimeric antigen receptor T Cells. Clin Infect Dis. 2018 Aug 1;67(4):533–540.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016 Jun;6(6):664–679.
   PubMed Web of Science ®Google Scholar
• Hashmi H, Bachmeier C, Chavez JC, et al. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. Br J Haematol. 2019 Aug 13;187(2)e35-e38.
   Web of Science ®Google Scholar
• National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188–195.
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015 Sep 2;7(303):303ra139.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan;15(1):47–62.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625–638.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016 Jun 30;127(26):3321–3330.
   PubMed Web of Science ®Google Scholar
• Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019 May;94(S1):S42–S49.
   PubMedGoogle Scholar
• Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019 Mar;34:45–55.
   PubMed Web of Science ®Google Scholar
• Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018 Aug;8(8):958–971.
   PubMed Web of Science ®Google Scholar
• Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018 Jun;24(6):739–748.
   PubMed Web of Science ®Google Scholar
• Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018 Jun;24(6):731–738.
   PubMed Web of Science ®Google Scholar
• Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133(7):697–709.
   PubMed Web of Science ®Google Scholar
• Staedtke V, Bai RY, Kim K, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018 Dec;564(7735):273–277.
   PubMed Web of Science ®Google Scholar
• Tocilizumab product insert. 2016 Sept [cited 2019 Sept 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125276s107_125472s018lbl.pdf
   Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509–1518.
   PubMed Web of Science ®Google Scholar
• Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T Cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018 Aug;23(8):943–947.
   PubMed Web of Science ®Google Scholar
• Topp MS, Meerten T, Wermke M, et al. Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) [Abstract]. J Clin Oncol. 2019;37(15):7558.
   Web of Science ®Google Scholar
• Gardner RA, Ceppi F, Rivers J, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019 Dec 12;134(24):2149–2158.
   PubMed Web of Science ®Google Scholar
• Yescarta product insert. 2017 [cited 2020 Jan 31]. Available from: https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert—YESCARTA.pdf
   Google Scholar
• Liu Y, Chen X, Wang D, et al. Hemofiltration successfully eliminates severe cytokine release syndrome following CD19 CAR-T-cell therapy. J Immunother. 2018 Nov–Dec;41(9):406–410.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008 Nov 15;112(10):3959–3964.
   PubMed Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory,aggressive Non-Hodgkin Lymphoma (NHL). Blood. 2017;130:1547.
   Web of Science ®Google Scholar
• Oved JH, Barrett DM, Teachey DT. Cellular therapy: immune-related complications. Immunol Rev. 2019 Jul;290(1):114–126.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) v4.03. 2010. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_4.03.xlsx
   Google Scholar
• Abramson JS, Gordon LI, Palomba ML, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36(15):7505–7505.
   Web of Science ®Google Scholar
• Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017 Dec;7(12):1404–1419.
   PubMed Web of Science ®Google Scholar
• Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019 Jun;37(Suppl 1):48–52.
   PubMed Web of Science ®Google Scholar
• Poh A. JCAR015 in ALL: a root-cause investigation. Cancer Discov. 2018 Jan;8(1):4–5.
   Web of Science ®Google Scholar
• Torre M, Solomon IH, Sutherland CL, et al. Neuropathology of a case with fatal CAR T-cell-associated cerebral edema. J Neuropathol Exp Neurol. 2018 Jul 6;77:877–882.
   PubMed Web of Science ®Google Scholar
• Gust J, Finney OC, Li D, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019 Jul;86(1):42–54.
   PubMed Web of Science ®Google Scholar
• Mahadeo KM, Khazal SJ, Abdel-Azim H, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019 Jan;16(1):45–63.
   PubMed Web of Science ®Google Scholar
• Traube C, Silver G, Kearney J, et al. Cornell assessment of pediatric delirium: a valid, rapid, observational tool for screening delirium in the PICU*. Crit Care Med. 2014 Mar;42(3):656–663.
   PubMed Web of Science ®Google Scholar
• Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity Associated with CD19-Targeted CAR-T cell therapies. CNS Drugs. 2018 Dec;32(12):1091–1101.
   PubMed Web of Science ®Google Scholar
• Taraseviciute A, Tkachev V, Ponce R, et al. Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 2018 Jun;8(6):750–763.
   PubMed Web of Science ®Google Scholar
• Nellan A, McCully CML, Cruz Garcia R, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood. 2018 Aug 9;132(6):662–666.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Locke FL, Haroun F. Advances in aggressive lymphoma from the 2017 American Society of Hematology annual meeting and exposition. Clin Adv Hemato Oncol. 2018;16(2):20.
   PubMed Web of Science ®Google Scholar
• Shah B, Huynh V, Sender LS, et al. High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): preliminary Results of the ZUMA-3 and ZUMA-4 Trials [Abstract]. Blood. 2016;128:2803.
   Web of Science ®Google Scholar
• van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug;15(9):966–974.
   PubMed Web of Science ®Google Scholar
• Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020 Feb;72(2):326–334.
   PubMed Web of Science ®Google Scholar
• Anakinra product insert. 2012 [cited 2019 Sept 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/103950-0_Kineret.cfm
   Google Scholar
• La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019 Jun 6;133(23):2465–2477.
   PubMed Web of Science ®Google Scholar
• Weber EW, Lynn RC, Sotillo E, et al. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 2019 Mar 12;3(5):711–717.
   PubMed Web of Science ®Google Scholar
• Wang X, Chang WC, Wong CW, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011 Aug 4;118(5):1255–1263.
   PubMed Web of Science ®Google Scholar
• Zhou X, Dotti G, Krance RA, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25;125(26):4103–4113.
   PubMed Web of Science ®Google Scholar